FDA Laengz Atezolizumab Caux Chemotherapy Weic Stage III dMMR Colon Cancer, Bun Disease-Free Survival Risk Dingh Buangv
US Food and Drug Administration October 8 laengz atezolizumab (Tecentriq, Genentech) juangc caux fluoropyrimidine caux oxaliplatin weic adjuvant treatment adult caux pediatric patients 2 hnyangx a'fai hlo maaih Stage III mismatch repair-deficient (dMMR) colon cancer. Subcutaneous formulation, atezolizumab caux hyaluronidase-tqjs (Tecentriq Hybreza), duqv laengz caux doic chemotherapy weic patients 12 a'fai hlo maaih daaic 40 kg.
Laengz nyei jauv yiem ATOMIC/ML39057 trial, 711 adults caux yietc pediatric patient ninh mbuo zoux complete resection duqv randomized 1:1 taux atezolizumab caux 12 cycles mFOLFOX6 aengx luoqc ndieqc atezolizumab monotherapy, a'fai 12 cycles mFOLFOX6 hnangv. Hlo efficacy outcome, disease-free survival, bun hazard ratio 0.50 (95% CI 0.35–0.73; p=0.0001) — recurrence a'fai daaix nyei risk dingh buangv — maaih median disease-free survival maiv corc taux yietc bien.
FDA labeling maaih warnings weic immune-mediated adverse reactions, infusion-related reactions, stem-cell transplantation nyei complications caux embryo-fetal toxicity. Mismatch repair-deficient tumors se colon cancers ninh mbuo dau immunotherapy longx jiex, bun naaiv yiemc adjuvant options nyei hlo jaa; treatment nyei jauv yiem patient nyei oncology team yiem biomarker testing.
Daaih Dieh: GSM · United States (English edition · Zinh Ndaangc Chinese edition)
Yaangh: 癌组织中的T细胞显微图像。Image: NIH Image Gallery, public domain
